Ultragenyx ranted EU orphan drug designation for KRN23 for treatment of XLH
Ultragenyx announced the EC has granted orphan medicinal product designation for recombinant human monoclonal IgG1 antibody for fibroblast growth factor 23 (KRN23 or UX023) for treatment of X-linked hypophosphatemia. October 30, 2014